Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,115.68 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly (NYSE:LLY) Beats Expectations in Strong Q2 CY2026, Full-Year Outlook Slightly Exceeds Expectations

Today 6:49 EDT

Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 47.7% year on year t...

Via StockStory

Elanco’s (NYSE:ELAN) Q2 CY2026: Strong Sales, Stock Soars

Today 6:34 EDT

Animal health company Elanco (NYSE:ELAN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 10.2% year on year to $1.37 billion...

Via StockStory

AMD, Walt Disney And 3 Stocks To Watch Heading Into Wednesday ↗

Today 2:22 EDT

U.S. stock futures up, Eli Lilly, AMD, Disney, SpaceX and SanDisk expected to release earnings. SpaceX beats estimates, shares down 7.5%.

Via Benzinga

$100 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today ↗

August 04, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 20 years by 6.87% on an annualized basis producing an average annual return of 16.31%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Eli Lilly (NYSE:LLY) Stands Out as a High-Growth Momentum Leader ↗

August 04, 2026

Via Chartmill

Eli Lilly Could Swing $65.9 Billion After Earnings ↗

August 04, 2026

Earnings coming Wed with varying volatility levels. Benzinga Pro selected list incl. relatively muted setups to double-digit swings. Top pick Eli Lilly.

Via Benzinga

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings ↗

August 04, 2026

Eli Lilly investors may be eyeing potential gains from the company’s annual dividend yield of 0.62% ($6.92 a year).

Via Benzinga

Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started? ↗

August 04, 2026

Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.

Via The Motley Fool

Amazon and Microsoft Gained a Combined $1.04 Trillion in Market Cap in 2 Days, While Apple and Meta Platforms Lost $510 Billion. Meet the Vanguard ETF That's Built for This Exact Market. ↗

August 04, 2026

With volatility heating up, some investors may prefer the straightforward approach of the Vanguard Mega Cap Growth ETF.

Via The Motley Fool

What To Expect From Eli Lilly’s (LLY) Q2 Earnings

August 03, 2026

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Wednesday morning. Here’s what investors should know. Eli Lilly beat analys...

Via StockStory

Topics Artificial Intelligence

Inspire Medical Systems Q2 Earnings Call Highlights ↗

August 03, 2026

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The...

Via MarketBeat

Topics Earnings

Exploring the top movers within the S&P500 index during today's session. ↗

August 03, 2026

Via Chartmill

Is Eli Lilly Stock Running out of Steam? ↗

August 03, 2026

The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.

Via The Motley Fool

Eli Lilly Could Swing Over $76 Billion In Value After Earnings ↗

August 03, 2026

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings...

Via Benzinga

Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? ↗

August 03, 2026

XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?

Via The Motley Fool

Topics ETFs

Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 02, 2026

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

Via The Motley Fool

XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? ↗

August 01, 2026

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

Via The Motley Fool

Topics ETFs Intellectual Property

Prediction: Eli Lilly Will Be Worth $2 Trillion by 2031 ↗

August 01, 2026

And it will likely be the first company in the sector to get there.

Via The Motley Fool

XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? ↗

August 01, 2026

PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility.

Via The Motley Fool

Topics ETFs

Healthcare Stocks Are Having a Good Year. Should You Buy a Fidelity or iShares ETF to Profit? ↗

August 01, 2026

FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences.

Via The Motley Fool

Topics ETFs

Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip? ↗

July 31, 2026

With the stock near a 5-year low, is it worth a look?

Via The Motley Fool

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore. ↗

July 31, 2026

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

Via The Motley Fool

XLV vs. IHE: Which Healthcare ETF Is the Better Buy? ↗

July 31, 2026

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

Via The Motley Fool

Topics ETFs Intellectual Property

Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels ↗

July 31, 2026

Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure.

Via Investor's Business Daily

Which Healthcare ETF Is the Better Buy: Fidelity's FHLC or Invesco's Equal-Weight RSPH? ↗

July 31, 2026

FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.

Via The Motley Fool

Topics ETFs

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target ↗

July 30, 2026

There are other reasons to pay attention to Viking Therapeutics.

Via The Motley Fool

VHT vs. PBE: Which Health Care ETF Is the Better Buy? ↗

July 30, 2026

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost...

Via The Motley Fool

Topics ETFs

Jim Cramer: Eli Lilly Is A 'Good Company,' But Doesn't 'Really Care For' This Quantum Stock ↗

July 30, 2026

CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage...

Via Benzinga

Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now ↗

July 29, 2026

But is that performance sustainable?

Via The Motley Fool

3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗

July 29, 2026

They may profit from the rapidly growing GLP-1 market in very different ways.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Eli Lilly (NY:LLY)

All News about Eli Lilly

Starting at /week.